Stock Track | INSILICO Soars 11.79% Intraday on $2.75 Billion Eli Lilly AI Drug Collaboration

Stock Track04-01

INSILICO's stock price surged 11.79% during intraday trading on Wednesday, marking a significant upward movement for the AI-driven biotech company.

The sharp rise follows the announcement of a major collaboration with pharmaceutical giant Eli Lilly. The agreement grants Eli Lilly exclusive rights to commercialize a GLP-1 diabetes drug developed using INSILICO's proprietary artificial intelligence technology. The deal includes an upfront payment of $115 million to INSILICO and holds a total potential value of up to $2.75 billion. Furthermore, Eli Lilly will gain access to INSILICO's AI platform, with both companies planning to jointly use its "AI engine" to accelerate drug discovery across multiple therapeutic areas.

This partnership has fueled positive market sentiment, although it also sparked speculation about a potential acquisition of INSILICO. The company's founder and CEO, Alex Zhavoronkov, has firmly denied such rumors, stating a preference to maintain independence at the company's current valuation. He emphasized INSILICO's strategic focus on leveraging China's unique infrastructure and policy support for AI-driven drug discovery, which requires extensive experimental validation.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1157401535?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 11:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1157401535","market":"nz","top_or_hot":-1,"title":"Stock Track | INSILICO Soars 11.79% Intraday on $2.75 Billion Eli Lilly AI Drug Collaboration","media":"Stock Track","content":"<p>INSILICO's stock price surged 11.79% during intraday trading on Wednesday, marking a significant upward movement for the AI-driven biotech company.</p><p>The sharp rise follows the announcement of a major collaboration with pharmaceutical giant Eli Lilly. The agreement grants Eli Lilly exclusive rights to commercialize a GLP-1 diabetes drug developed using INSILICO's proprietary artificial intelligence technology. The deal includes an upfront payment of $115 million to INSILICO and holds a total potential value of up to $2.75 billion. Furthermore, Eli Lilly will gain access to INSILICO's AI platform, with both companies planning to jointly use its \"AI engine\" to accelerate drug discovery across multiple therapeutic areas.</p><p>This partnership has fueled positive market sentiment, although it also sparked speculation about a potential acquisition of INSILICO. The company's founder and CEO, Alex Zhavoronkov, has firmly denied such rumors, stating a preference to maintain independence at the company's current valuation. He emphasized INSILICO's strategic focus on leveraging China's unique infrastructure and policy support for AI-driven drug discovery, which requires extensive experimental validation.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | INSILICO Soars 11.79% Intraday on $2.75 Billion Eli Lilly AI Drug Collaboration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | INSILICO Soars 11.79% Intraday on $2.75 Billion Eli Lilly AI Drug Collaboration\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-01 11:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>INSILICO's stock price surged 11.79% during intraday trading on Wednesday, marking a significant upward movement for the AI-driven biotech company.</p><p>The sharp rise follows the announcement of a major collaboration with pharmaceutical giant Eli Lilly. The agreement grants Eli Lilly exclusive rights to commercialize a GLP-1 diabetes drug developed using INSILICO's proprietary artificial intelligence technology. The deal includes an upfront payment of $115 million to INSILICO and holds a total potential value of up to $2.75 billion. Furthermore, Eli Lilly will gain access to INSILICO's AI platform, with both companies planning to jointly use its \"AI engine\" to accelerate drug discovery across multiple therapeutic areas.</p><p>This partnership has fueled positive market sentiment, although it also sparked speculation about a potential acquisition of INSILICO. The company's founder and CEO, Alex Zhavoronkov, has firmly denied such rumors, stating a preference to maintain independence at the company's current valuation. He emphasized INSILICO's strategic focus on leveraging China's unique infrastructure and policy support for AI-driven drug discovery, which requires extensive experimental validation.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03696","symbol_name":"英矽智能","start_time":0,"source_url":"","article_id":"1157401535","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1157401535","pubTimestamp":1775014311,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"INSILICO's stock price surged 11.79% during intraday trading on Wednesday, marking a significant upward movement for the AI-driven biotech company.The sharp rise follows the announcement of a major...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03696":"英矽智能"},"translate_title":"个股追踪|英矽智能盘中大涨11.79%受27.5亿美元礼来AI药物合作","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03696":1},"content_text":"INSILICO's stock price surged 11.79% during intraday trading on Wednesday, marking a significant upward movement for the AI-driven biotech company.The sharp rise follows the announcement of a major collaboration with pharmaceutical giant Eli Lilly. The agreement grants Eli Lilly exclusive rights to commercialize a GLP-1 diabetes drug developed using INSILICO's proprietary artificial intelligence technology. The deal includes an upfront payment of $115 million to INSILICO and holds a total potential value of up to $2.75 billion. Furthermore, Eli Lilly will gain access to INSILICO's AI platform, with both companies planning to jointly use its \"AI engine\" to accelerate drug discovery across multiple therapeutic areas.This partnership has fueled positive market sentiment, although it also sparked speculation about a potential acquisition of INSILICO. The company's founder and CEO, Alex Zhavoronkov, has firmly denied such rumors, stating a preference to maintain independence at the company's current valuation. He emphasized INSILICO's strategic focus on leveraging China's unique infrastructure and policy support for AI-driven drug discovery, which requires extensive experimental validation.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1157401535","isCrawlerRequest":true}